Menu
IHBT

Clinical Trials

EudraCT 2018-004789-32, ÚHKT-CAR19-01, NCT05054257: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. (Principal Investigator: MUDr. Jan Vydra, Ph.D., jan.vydra@uhkt.cz)

Eudra CT 2017-004577-14, Blina-Cell, NCT04554485: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz)

EudraCT 2019-004540-29, Pona-Cell, NCT04554459: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia in adults. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz)

EudraCT 2016-004942-27, EWALL-INO; P16/11: A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz)

EudraCT 2017-002331-41, HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Ran-domized Prospective European Trial. (Principal Investigator: MUDr. Markéta Šťastná Marková, CSc., marketa.markova@uhkt.cz )

EudraCT 2022-000302-10, ÚHKT-COVID19: Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system. (Principal Investigator: MUDr. Markéta Šťastná Marková, CSc., marketa.markova@uhkt.cz)

EUPAS17848, Protocol 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz)

EudraCT 2017-003190-34, Protocol ACE-536-MDS-002: A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alfa for treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes in ESA naive subjects who requires red blood cell transfusion. (Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

EudraCT 2015‐004856‐24, Protocol AC220-A-U302: A double-blind, placebo-controlled phase 3 study of quizartinib (AC220) administered in combination with induction and consolidation chemotherapy, and administered as maintenance therapy in subjects 18 to 75 years old with newly diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First) EudraCT 2012-003457-28, Protocol CC-486-AML-001: A randomized, double-blind, placebo controlled phase 3 study to compare efficacy and safety Oral Azacitidine plus best supportive care versus as Maintenance Therapy in subject with Acute Myeloid Leukemia in complete remission. (Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

NTC02053480, Protocol AG348-C-008: A long-term global observational study in patients with pyruvate kinase deficiency (Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

EudraCT 2019-002089-11, Protocol CMBG453B12301: A randomized, double-blind, placebo-controlled multi-centre phase 3 study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

EU/1/13/839/002, Protocol Ponderosa: An observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose (Principal Investigator: MUDr. Hana Klamová, CSc., hana.klamova@uhkt.cz)

EudraCT 2019-002217-19, Protocol M19-708: Protocol M19-708: A randomized, open-label, 2-arm, multicentre phase 3 study of venetoclax and azacitidine versus standard of care as maintenance therapy for patients with Acute Myeloid Leukemia in first remission after conventional chemotherapy (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz)

EudraCT 2019-003221-16, Protocol HALF: A prospective phase 2 clinical trial evaluating nationwide the efficacy and safety of discontinuation of tyrosine kinase inhibitors after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission (Principal Investigator: MUDr. Hana Klamová, CSc., hana.klamova@uhkt.cz)

EudraCT 2020-000744-55, Protocol M15-954 (Verona): A randomized, double-blind, phase 3 study evaluating the safety and efficacy of venetoclax in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (higher-risk MDS) (Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

EudraCT 2019-000720-17, Protocol MOM-M281-006: Efficacy and safety of M281 in adult patients with warm form of autoimmune hemolytic anemia: a multicentre, randomized, double-blind, placebo-controlled clinical trial ((Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

EudraCT 2020-000597-26, Protocol BO42161: A randomized, unblinded, active-controlled, multicentre phase 3 study evaluating the safety and efficacy of crovalimab compared to eculizumab in adult and adolescent patients with PNH currently receiving treatment with complement system inhibitors (Principal Investigator: prof. MUDr. Jaroslav Čermák, CSc., jaroslav.cermak@uhkt.cz)

EudraCT 2019-002621-30, Protocol M19-603: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) (Principal Investigator: MUDr. Jan Vydra, Ph.D., jan.vydra@uhkt.cz)

EudraCT 2022-000995-21, Protocol CABL001J12302: A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Principal Investigator: MUDr. Hana Klamová, CSc., hana.klamova@uhkt.cz)

EudraCT 2022-001177-31, Protocol EFC16521 MAYARI: An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura (Principal Investigator: MUDr. Viera Pohlreichová, viera.pohlreichova@uhkt.cz )


Quick contact

Stem cell transplant coordinator
+420 221 977 486

Transplant Unit
+420 221 977 229

Ambulance
+420 221 977 315

Inpatient Department
+420 221 977 226

ICU
+420 221 977 294


Opening hours

Ambulance
Mo – Fr: 7:00–18:00
Weekends: 9:00–13:00

Inpatient departments
Non stop

How to find us

map

Ústav hematologie a krevní transfuze
(​Institute of Hematology and Blood Transfusion)

U Nemocnice 2094/1
128 00 Praha 2

The nearest underground station: Karlovo náměstí (line B)

The nearest tram station: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

The nearest bus station: U Nemocnice (148), Karlovo náměstí (176)

How to get here